Amivantamab-vmjw (Rybrevant)
Dilution requiredFull monograph review pending
U.S. label preparation
Rybrevant · Dilution required
- Preparation
- For each 350 mg IV vial used, replace 7 mL of diluent in a 250 mL bag with 7 mL of drug. Use 0.9% sodium chloride or 5% dextrose. The final volume is 250 mL.
- Administration and handling
- Use the label's infusion-rate tables for the scheduled dose. Rybrevant Faspro is a different, subcutaneous product.
Product and source details
Janssen Biotech, Inc. · BLA761210
Product NDC: 57894-501
SPL effective 2025-11-11 | SPL version 17. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.